STOCK TITAN

Lexaria Bioscience Corp. Warrant - LEXXW STOCK NEWS

Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.

Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.

Rhea-AI Summary

Lexaria Bioscience Corp. announced it received US$3,817,643 from the exercise of warrants linked to its January 2021 public offering. A total of 580,189 shares were issued at an exercise price of US$6.58 per share. The funds will support its ongoing research programs and general corporate needs, with sufficient capital to sustain operations well into 2022. Lexaria's DehydraTECH technology enhances drug absorption and is licensed to various companies, including a major tobacco firm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful achievement of all objectives in its 2021 antiviral drug program. The company tested five compounds from three antiviral drug classes, achieving up to a three-fold increase in oral drug absorption with its DehydraTECH technology. The results showed significant improvements in bioavailability for drugs like Colchicine and Remdesivir. Next steps include larger efficacy evaluations in infected animals and pursuing collaborations for further product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced positive results from its study VIRAL-A20-3, demonstrating that its DehydraTECH technology significantly enhances the delivery of colchicine, a drug with potential anti-inflammatory effects useful in treating SARS-CoV-2/COVID-19 symptoms. The study showed a 91% improvement in peak concentration and a 167% increase in total drug delivery compared to control. The findings suggest potential for improved bioavailability of colchicine, which may allow for lower dosing and enhanced therapeutic effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced promising results from its antiviral drug study, VIRAL-MC21-1, conducted by the National Research Council of Canada. The study confirms that DehydraTECH technology maintains the chemical stability of five tested antiviral drugs, supporting quicker regulatory approvals via the FDA's 505(b)(2) pathway. Key drugs include remdesivir and colchicine, which are associated with COVID-19 treatment. Lexaria plans to seek collaborations with pharmaceutical partners to enhance the application of DehydraTECH in antiviral therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. has been granted its first patent in Japan, strengthening its intellectual property portfolio, now totaling 20 patents globally. This patent focuses on stable, ready-to-drink beverage compositions containing lipophilic active agents. Lexaria's innovative DehydraTECH platform enhances the bio-absorption of non-psychoactive cannabinoids and NSAIDs, allowing for healthier ingestion methods. The company aims to expand its patent applications globally, targeting a market of nearly 4 billion people.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced plans to voluntarily delist its common shares from the Canadian Securities Exchange (CSE) effective July 7, 2021. Starting July 8, 2021, trading will be consolidated on the Nasdaq Capital Markets, where the majority of trading has already occurred since its Nasdaq debut in January 2021. This decision aims to enhance shareholder liquidity and reduce operational costs, allowing the company to focus its resources on applied research and development programs. Lexaria's shares remain qualified investments for Canadian Registered Savings Plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. held its 2021 Annual Meeting on June 28, with 2,735,413 shares represented, comprising 53.6% of its issued capital. Shareholders voted on several proposals, including the election of directors and the appointment of auditors. Key votes included 97.2% approval for Chris Bunka's directorship and 99.2% for auditor appointment. However, an amendment to the Equity Incentive Plan was only 68.3% approved. The company’s DehydraTECH technology continues to enhance drug delivery capabilities across various products, with a robust patent portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports promising results from its study VIRAL-A20-2, demonstrating that its DehydraTECH technology significantly enhances the oral bioavailability of remdesivir and ebastine. Findings indicate that drug levels in the bloodstream can be increased by up to three times compared to non-processed drugs. This improvement may increase the efficacy of these antiviral drugs against SARS-CoV-2. The study was conducted on male rats, with results showing significant improvements in drug delivery metrics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has provided a progress report on its 2021 applied R&D program, focusing on the enhanced drug delivery capabilities of its DehydraTECH technology. Significant studies include tolerability and pharmacokinetic evaluations for antiviral drugs and blood pressure testing using CBD. Key studies reported include VIRAL-A20-2 and VIRAL-A20-3 for antiviral drugs, and follow-up studies on blood pressure and NSAIDs. All studies are fully funded and aim to establish commercial partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. has completed dosing in its first human clinical study, HYPER-H21-1, testing the efficacy of its DehydraTECH 2.0 CBD formulation for hypertension treatment. The study involved 24 participants aged 45 to 65, all of whom tolerated the treatment well with no serious adverse effects. Preliminary results are expected by July or August 2021, ahead of the previous Q3 timeline. The company is set to commence the second study, HYPER-H21-2, shortly, involving 16 participants and aiming for swift data analysis and reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?

The current stock price of Lexaria Bioscience Warrant (LEXXW) is $0.8 as of December 24, 2024.

What is Lexaria Bioscience Corp. known for?

Lexaria Bioscience Corp. is known for its patented drug delivery technology, DehydraTECH, which enhances the absorption of active pharmaceutical ingredients.

In which segments does Lexaria operate?

Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate.

What are the key benefits of DehydraTECH?

DehydraTECH has shown to increase bio-absorption, reduce onset times, and mask unwanted tastes of active pharmaceutical ingredients.

What is the main goal of Lexaria Bioscience Corp.?

Lexaria aims to revolutionize drug delivery methods and improve outcomes through ongoing research and innovation.

How does DehydraTECH impact drug delivery across the blood-brain barrier?

DehydraTECH has evidenced an ability to deliver some drugs more effectively across the blood-brain barrier, which is crucial for centrally active compounds.

What is the significance of Lexaria's intellectual property portfolio?

With 43 patents granted worldwide, Lexaria's intellectual property portfolio plays a key role in supporting its future business objectives.

Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?

GLP-1 drugs like Rybelsus and Ozempic are owned and manufactured by Novo Nordisk.

What is the focus of Lexaria's ongoing research?

Lexaria's ongoing research aims to validate the effectiveness of DehydraTECH in delivering various active pharmaceutical ingredients orally and improving tolerability.

How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?

Lexaria's latest Study aims to evaluate the absorption and effectiveness of DehydraTECH-processed tirzepatide in an oral dosage format, potentially offering improved tolerability and measurable drug levels in the bloodstream.

What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?

Lexaria's focus on enhancing drug absorption, reducing onset times, and addressing taste issues sets it apart as a leading innovator in drug delivery platforms.

Lexaria Bioscience Corp. Warrant

Nasdaq:LEXXW

LEXXW Rankings

LEXXW Stock Data

13.23M
Biotechnology
Pharmaceutical Preparations
Link
United States of America
KELOWNA